

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Andrews et al.

Serial No.: 10/522,958

Filed: January 31, 2005

Title: Thiophene Compounds

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 C.F.R. § 1.821-1.825

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


Sir:

Applicants hereby respectfully request that the sequence listing filed on January 31, 2005 be replaced with the attached corrected sequence listing, wherein line 213 is changed from "baculovirus infected T.ni cells" to "Artificial Sequence" and the descriptor line 223 is added. The sequences have not been changed.

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted



Lorie Ann Morgan  
Attorney of Record, Reg. No. 38,181

26 March 2008  
Date

GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398 US  
Phone: 919-483-8222  
Facsimile: 919-483-7988